Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02588131
Other study ID # NIBIT-MESO-1
Secondary ID
Status Recruiting
Phase Phase 2
First received October 26, 2015
Last updated October 26, 2015
Start date October 2015
Est. completion date March 2018

Study information

Verified date October 2015
Source Italian Network for Tumor Biotherapy Foundation
Contact Luana Calabro', MD, PhD
Phone +39-0577586116
Email l.calabro@ao-siena.toscana.it
Is FDA regulated No
Health authority Italy: The Italian Medicines Agency
Study type Interventional

Clinical Trial Summary

This phase 2, open-label, single arm study aims to evaluate the efficacy of tremelimumab in combination with the anti-PD-L1 MEDI4736 in patients with unresectable malignant mesothelioma subjects


Description:

The prognosis of malignant mesothelioma (MM) patients remains dismal and effective treatment represents a high un-met medical need. Investigators have recently reported promising clinical activity of the anti-CTLA-4 mAb tremelimumab in pre-treated MM patients: disease control rate (DCR) was 31%, and survival rate at 1- and 2-years were 48.3% and 36.7%, respectively. These initial findings were corroborated by a second study in which, based on retrospective pharmacokinetic analyses, an intensified schedule of tremelimumab was utilized. Fifty-two % of patients achieved a DCR (median duration 10.9 months). These intriguing clinical results and the emerging efficacy of immunomodulatory mAb targeting the PD-1/PD-L1 axis in different tumor types, prompted us to design the NIBIT-MESO-1 study aimed to investigate the efficacy of tremelimumab combined with the anti-PD-L1 MEDI4736 in MM patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date March 2018
Est. primary completion date June 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Willing and able to give written informed consent.

- Histologic diagnosis of malignant mesothelioma.

- Subjects who have refused a first line platinum-based chemotherapy, or subjects in progression of disease after a maximum of one line of platinum-based therapy for advanced disease.

- Disease not amenable to curative surgery.

- Measurable disease, per modified Response Evaluation Criteria in Solid Tumor [RECIST] for pleural mesothelioma or RECIST version 1.1 for peritoneal mesothelioma).

- Life expectancy = 12 weeks.

- ECOG performance status of 0 or 1

- Normal laboratory tests

- Negative screening tests for HIV, Hepatitis B, and Hepatitis C.

- Availability of archival tumor tissue or feasibility to perform a new tumor biopsy at screening phase.

- Men and women, of and over 18 years old. Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception. WOCBP should use an adequate method to avoid pregnancy for 180 days after the last dose of investigational drug.

Exclusion Criteria:

- Involvement in the planning and/or conduct of the study.

- Participation in another clinical study with an investigational product during the last 6 weeks.

- Any previous treatment with a CTLA4, PD-1 or PD-L1 inhibitor, including tremelimumab or MEDI4736.

- History of another primary malignancy except for: malignancy treated with curative intent and with no known active disease =3 years before the first dose of study drug and of low potential risk for recurrence. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease. Adequately treated carcinoma in situ without evidence of disease eg, cervical cancer in situ.

- Receipt of the last dose of anti-cancer therapy = 6 weeks prior to the first dose of study drug.

- Mean QT interval corrected for heart rate (QTc) =470 ms using Bazett's Correction.

- Current or prior use of immunosuppressive medication within 28 days before the first dose of tremelimumab and MEDI4736, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid.

- Any unresolved toxicity (CTCAE grade >2) from previous anti-cancer therapy.

- Any prior Grade >3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE >Grade 1. Active or prior documented autoimmune or inflammatory disorders

- History of primary immunodeficiency or allogeneic organ transplant.

- History of hypersensitivity to tremelimumab or MEDI4736 or any excipient.

- Uncontrolled intercurrent illness including, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses

- Known history of previous clinical diagnosis of tuberculosis.

- History of leptomeningeal carcinomatosis.

- Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving tremelimumab and MEDI4736.

- Symptomatic or uncontrolled brain metastases requiring concurrent treatment, inclusive of but not limited to surgery, radiation and/or corticosteroids.

- Subjects with uncontrolled seizures.

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
tremelimumab plus MEDI4736
tremelimumab1 mg/kg i.v over 60 minutes plus MEDI 4736 20 mg/kg i.v every four weeks for 4 doses, then MEDI4736 20 mg/kg IV every four weeks for additional 9 doses.

Locations

Country Name City State
Italy Medical Oncology and Immunotherapy Division, University Hospital of Siena Siena

Sponsors (2)

Lead Sponsor Collaborator
Italian Network for Tumor Biotherapy Foundation AstraZeneca

Country where clinical trial is conducted

Italy, 

References & Publications (4)

Antonia et al. A Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients with advanced non-small cell lung cancer (NSCLC). ASCO 2015 (Abstract #3014).

Calabrò L, Ceresoli GL, di Pietro A, Cutaia O, Morra A, Ibrahim R, Maio M. CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy? Cancer Immunol Immunother. 2015 Jan;64(1):105-12. doi: 10.1007/s00262-014-1609-9. Epub 2014 Sep 19. Review. — View Citation

Calabrò L, Morra A, Fonsatti E, Cutaia O, Amato G, Giannarelli D, Di Giacomo AM, Danielli R, Altomonte M, Mutti L, Maio M. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2013 Oct;14(11):1104-11. doi: 10.1016/S1470-2045(13)70381-4. Epub 2013 Sep 11. — View Citation

Calabrò L, Morra A, Fonsatti E, Cutaia O, Fazio C, Annesi D, Lenoci M, Amato G, Danielli R, Altomonte M, Giannarelli D, Di Giacomo AM, Maio M. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. Lancet Respir Med. 2015 Apr;3(4):301-9. doi: 10.1016/S2213-2600(15)00092-2. Epub 2015 Mar 26. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary immune-related (ir)- objective response rate (ORR) proportion of subjects with complete response [CR] or partial Response [PR]) according to the ir-modified-RECIST or ir-RECIST 1.1 in pleural or peritoneal subjects, respectively. 60 weeks No
Secondary Immune-related-Disease control rate (ir-DCR) proportion of subjects with ir-CR, ir-PR, ir-stable disease according to the ir-modified-RECIST or ir-RECIST 1.1 in pleural or peritoneal subjects, respectively 60 weeks No
Secondary Disease control rate (DCR) proportion of subjects with CR, PR, stable disease according to the modified-RECIST or RECIST 1.1 in pleural or peritoneal subjects, respectively 60 weeks No
Secondary Immune-related-progression-free-survival (PFS) ir-PFS per ir-modified-RECIST or ir-RECIST-1.1 for pleural or peritoneal mesothelioma respectively, will be defined as the time between the date of randomization and the date of progression or death 60 weeks No
Secondary progression-free-survival (PFS) PFS per modified-RECIST or RECIST-1.1 for pleural or peritoneal mesothelioma respectively, will be defined as the time between the date of randomization and the date of progression or death 60 weeks No
Secondary Overall survival (OS) Overall Survival (OS) is defined as the time from randomization until the date of death. For those subjects who have not died, OS will be censored at the recorded last date of subject contact, and for subjects with a missing recorded last date of contact, OS will be censored at the last date the subject was known to be alive. 120 weeks No
Secondary Safety (adverse events) The safety endpoints include adverse events (AEs) and serious adverse events (SAEs). Reporting of safety, extent of exposure, concomitant medications and discontinuation of study therapy will be based on all subjects who received at least 1 dose of treatment. Toxicity will be registered according to the NCICTC v 4.0 120 weeks Yes
Secondary Immune-related-ORR based on PD-L1 tumor expression proportion of subjects with PD-L1 positive or negative tumor expression who achieved a complete response [CR] or partial Response [PR]) according to the ir-modified-RECIST or ir-RECIST 1.1 in pleural or peritoneal subjects, respectively. 60 weeks No
Secondary Immune-related-Disease control rate based on PD-L1 tumor expression proportion of subjects with PD-L1 positive or negative tumor expression who achieved a CR, PR, stable disease according to the ir-modified-RECIST or ir-RECIST 1.1 in pleural or peritoneal subjects, respectively 60 weeks No
Secondary Immune-related-progression- free-survival based on PD-L1 tumor expression ir-PFS per ir-modified-RECIST or ir-RECIST-1.1 for pleural or peritoneal mesothelioma respectively, will be defined in subjects with PD-L1 positive or negative tumor expression as the time between the date of randomization and the date of progression or death 60 weeks No
Secondary Overall survival based on PD-L1 tumor expression Overall Survival (OS) is defined in subjects with PD-L1 positive or negative tumor expression as the time from randomization until the date of death. For those subjects who have not died, OS will be censored at the recorded last date of subject contact, and for subjects with a missing recorded last date of contact, OS will be censored at the last date the subject was known to be alive. 120 weeks No
See also
  Status Clinical Trial Phase
Terminated NCT04042480 - A Study of SGN-CD228A in Advanced Solid Tumors Phase 1
Active, not recruiting NCT04914897 - A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202) Phase 2
Recruiting NCT05910112 - Prospective Data Collection on Clinical, Radiological and Patient Reported Outcomes After Pleural Intervention
Recruiting NCT05930665 - Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma Phase 2
Recruiting NCT06362369 - A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy Phase 1/Phase 2
Completed NCT02414945 - TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients Phase 1/Phase 2
Recruiting NCT05714553 - NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours Phase 1/Phase 2
Completed NCT02585362 - Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program N/A
Completed NCT00299962 - Gene Therapy for Pleural Malignancies Phase 1
Terminated NCT04106973 - Mesothelioma Early Detection by VOCs
Not yet recruiting NCT06155279 - Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study) Phase 2
Not yet recruiting NCT06416930 - Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma Phase 2
Completed NCT01160458 - Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy Phase 2
Completed NCT02899195 - Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma Phase 2
Active, not recruiting NCT04040231 - Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma Phase 1
Completed NCT04430842 - Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S Phase 1
Completed NCT04324437 - eRAPID: Online Symptom Reporting in Lung Cancer N/A
Recruiting NCT03210298 - International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)
Terminated NCT00895648 - Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma Phase 2
Completed NCT00165516 - Extrapleural Pneumonectomy With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Amifostine and Sodium Thiosulfate Phase 2

External Links